Brainstorm Cell Therapeutics Inc.
BCLI
|
$0.5408
2.6%
2.73%
2.2K
|
Health Technology
(0.0% 1d) (48.2% 1m) (-79.8% 1y) (0.0% 2d) (0.0% 3d) (-9.7% 7d) (5.63% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 36,959,276
http://www.brainstorm-cell.com
Sec Filling | Patents | 32 employees
(US) Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.
sclerosis stem cell spinal cord multiple sclerosis t-cell parkinson bone msa nurown treatment ceiling
add to watch list Paper trade email alert is off
Press-releases
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Published: 2024-04-16 (Crawled : 23:00) - prnewswire.com
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
management company cell nurown trial therapeutics
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
Published: 2024-04-11 (Crawled : 10:00) - prnewswire.com
BCLI | $0.5408 2.6% 2.73% 2.2K
|
Health Technology
|
| O: -0.17%
H: 13.56%
C: -2.19%
nasdaq cell therapeutics market
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule - April 11, 2024
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
BCLI | $0.5408 2.6% 2.73% 2.2K
|
Health Technology
|
| O: -0.17%
H: 13.56%
C: -2.19%
nasdaq cell therapeutics market
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
Published: 2024-04-10 (Crawled : 10:00) - prnewswire.com
BCLI | $0.5408 2.6% 2.73% 2.2K
|
Health Technology
|
| O: -20.14%
H: 0.0%
C: 0.0%
als biomarker publication cell trial therapeutics
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
Published: 2024-04-09 (Crawled : 10:00) - prnewswire.com
BCLI | $0.5408 2.6% 2.73% 2.2K
|
Health Technology
|
| O: 10.45%
H: 0.0%
C: 0.0%
fda als cell for trial therapeutics agreement
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
Published: 2024-04-08 (Crawled : 12:00) - biospace.com/
BCLI | $0.5408 2.6% 2.73% 2.2K
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
update cell nurown program therapeutics
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-04-01 (Crawled : 12:00) - prnewswire.com
BCLI | $0.5408 2.6% 2.73% 2.2K
|
Health Technology
|
| O: 6.27%
H: 21.97%
C: 21.59%
year update cell therapeutics financial results
Amyotrophic Lateral Sclerosis Treatment Market size to grow by USD 663.7 million, 42% of market growth is expected in North America, Technavio
Published: 2024-03-12 (Crawled : 04:00) - prnewswire.com
ELDN | $1.57 -1.88% 3.03% 0
|
Manufacturing
|
| O: 1.73%
H: 1.7%
C: -7.39%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
DNLI | $16.82 -3.0% -3.15% 960K
|
Health Technology
|
| O: -0.6%
H: 0.74%
C: -3.66%
BCLI | $0.5408 2.6% 2.73% 2.2K
|
Health Technology
|
| O: -2.43%
H: 2.8%
C: -4.02%
BIIB | $192.16 -1.53% -1.57% 350
|
Health Technology
|
| O: -0.32%
H: 0.18%
C: -0.86%
expected sclerosis treatment growth market
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
Published: 2024-02-23 (Crawled : 11:00) - prnewswire.com
BCLI | $0.5408 2.6% 2.73% 2.2K
|
Health Technology
|
| O: 8.93%
H: 6.33%
C: -3.06%
nurown fda als cell trial therapeutics
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Golden Heaven Group Holdings Ltd. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GDHG
Published: 2023-12-31 (Crawled : 20:20) - prnewswire.com
BCLI | $0.5408 2.6% 2.73% 2.2K
|
Health Technology
| Email alert
Add to watchlist
GDHG | $0.216 -3.14% -3.0% 160K
|
| Email alert
Add to watchlist
first deadline group
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0001104659-24-034095 | 4 | 2024-03-14 | 2024-03-11 | Buy | A | 241935 | 423435 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 57% | 43% |
Top 10 Gainers
SINT | $0.0373 62.88% 65.82% 100M
|
Health Technology
INVO | $1.82 139.47% 49.67% 1.4M
|
Health Technology
HOLO | $2.24 -5.49% 27.74% 7.7M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
SMFL | $0.485 19.37% 21.18% 2.4M
|
Manufacturing
RCAT | $1.42 26.79% 20.0% 510K
|
Information
SECO | $0.3659 -2.06% 18.82% 1.3M
|
Retail Trade
VIAO | $0.262 0.77% 16.03% 14M
|
Electronic Technology
SBOW | $30.01 -5.75% 14.93% 43
|
Energy Minerals
Last 48 Hours Insiders Buying
IZEA | $2.53 1.2% -2.4% 0
|
Technology Services
|
00:00
RKT P 383 | $11.38 -0.52% 2.64% 5
|
Finance
|
22:30
CTRN P 18090 | $22.37 -1.41% -1.02% 0
|
Retail Trade
|
22:00
BRN P 10650 | $2.79 2.2% 0.0% 0
|
Energy Minerals
|
21:00
NEOG P 10000 | $12.14 -0.16% -0.16% 0
|
Health Technology
|
16:30
RMCF | $3.53 -3.16% -3.85% 0
|
Consumer Non-Durables
|
20:10